Daraxonrasib doubles survival for advanced pancreatic cancer patients

Pancreatic ductal adenocarcinoma (PDAC) remains the deadliest solid tumour, with a five‑year survival rate below 10 %. Most patients are diagnosed at an advanced stage, when surgical resection is no longer an option and systemic therapy is limited to cytotoxic regimens such as FOLFIRINOX or gemcitabine‑nab‑paclitaxel. Those treatments extend median overall survival (OS) to roughly six months but bring a heavy burden of nausea, neuropathy, and blood‑cell suppression.

The drug and its mechanism

Daraxonrasib is an oral, selective inhibitor of KRAS G12D, the most common KRAS mutation in PDAC (present in about 45 % of cases). By binding to the mutant pocket of KRAS, the compound blocks downstream MAPK signaling, curbing tumor proliferation without affecting wild‑type KRAS in healthy tissue. Early‑phase studies demonstrated dose‑dependent tumor shrinkage and a tolerable safety profile, prompting a global, double‑blind, phase‑III trial (DARAX‑3) that enrolled 500 patients with KRAS G12D‑mutated, unresectable or metastatic PDAC who had progressed after at least one line of chemotherapy.

Trial design and primary outcomes

• Population: 500 adults, median age 62, 58 % male, all confirmed KRAS G12D mutation.
• Intervention: Daraxonrasib 300 mg once daily, taken with food.
• Control: Investigator‑chosen standard chemotherapy (primarily gemcitabine‑nab‑paclitaxel).
• Primary endpoint: Median OS.
• Key secondary endpoints: Progression‑free survival (PFS), objective response rate (ORR), and treatment‑emergent adverse events (TEAEs).

Results that matter

Endpoint	Daraxonrasib	Standard chemo	Hazard ratio (HR)
Median OS	12.4 months	6.5 months	0.48 (95 % CI 0.39‑0.59)
Median PFS	5.8 months	3.1 months	0.55
ORR	22 %	9 %	—
Grade ≥ 3 TEAEs	31 %	58 %	—

Patients on daraxonrasib lived, on average, almost twice as long as those receiving conventional chemotherapy. The hazard ratio of 0.48 indicates a 52 % reduction in the risk of death. Moreover, the drug cut severe adverse events by almost half, with the most common side effects being mild fatigue and manageable rash.

Why the findings are significant

1. Targeted therapy for a mutation‑driven disease – KRAS has been labeled “undruggable” for decades. Daraxonrasib’s success validates the approach of directly hitting the mutant KRAS pocket, a strategy that could be extended to other KRAS‑mutant cancers.
2. Oral administration – Replacing infusion‑based regimens with a daily pill reduces hospital visits, a tangible quality‑of‑life improvement for patients already coping with a heavy symptom load.
3. Safety profile – The lower incidence of grade ≥ 3 toxicities may allow clinicians to keep patients on therapy longer, potentially translating into further survival gains.

Market positioning and commercial outlook

The drug is being developed by OncoNova Therapeutics, a mid‑size biotech that raised $210 million in a Series D round last year, led by Sequoia Capital and Bain Capital Ventures. The round was earmarked for late‑stage trial execution and scaling of manufacturing capabilities. With the DARAX‑3 data now published, OncoNova is in talks with the FDA about a priority review submission, targeting a 2028 launch in the United States and 2029 in Europe and Japan.

If approved, daraxonrasib would sit alongside existing chemotherapy backbones but likely become the preferred first‑line option for KRAS G12D‑positive patients, much as pembrolizumab is for MSI‑high tumours. The market for pancreatic cancer therapies is projected to exceed $5 billion by 2032, and a drug that can double survival while reducing toxicity would capture a sizable share.

Remaining questions

• Resistance mechanisms – Early data hint at secondary KRAS mutations emerging after 9‑12 months of therapy. Combination trials with SHP2 inhibitors are already slated for 2025.
• Broader KRAS coverage – Daraxonrasib is specific to G12D; patients with G12V or G12R mutations still lack a targeted option.
• Real‑world adherence – Oral agents rely on patient compliance; monitoring programs will be essential to ensure therapeutic levels.

Bottom line

The DARAX‑3 trial provides the most compelling evidence yet that a mutation‑specific oral agent can meaningfully extend life for patients with advanced pancreatic cancer, a disease that has long resisted therapeutic progress. While regulatory hurdles and longer‑term safety data remain, the data set a new benchmark for what is achievable in a space where few options have moved the needle.

For the full trial publication see New England Journal of Medicine – Daraxonrasib in KRAS‑G12D PDAC.